Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1109-1114

  Aklilu, M ^a   Stadler, W M ^a,b   Markiewicz, M ^a   Vogelzang, N J ^a,b   Mahowald, M ^a   Johnson, M ^a   Gajewski, T F ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

Author keywords

Clinical trial; Cytokines; Immunoregulation; Immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 2; INTERLEUKIN 4; PHYTOHEMAGGLUTININ; RITUXIMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; FLUSHING; GENE ACTIVATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IN VIVO STUDY; INJECTION SITE; INJECTION SITE REACTION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MALE; MELANOMA; METASTASIS POTENTIAL; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

EID: 4143138507     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh280     Document Type: Article

References (20)

1. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 1985; 135: 3623-3635.
2. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 1985; 135: 1488-1497.
3. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc 1994; 271: 907-913.
4. Keilholz U, Eggermont AM. The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology 2000; 58: 89-95.
5. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27: 194-203.
6. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12: 1572-1576.
7. Stadler WM, Vogelzang N. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995; 22: 67-73.
8. Brodt P, Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978; 121: 359-362.
9. Monach PA, Schreiber H, Rowley DA. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993; 55: 1356-1361.
10. Qin Z, Richter G, Schuler T et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627-630.
11. Manning TC, Rund LA, Gruber M et al. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol 1997; 159: 4665-4675.
12. Fallarino F, Gajewski T. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999; 163: 4109-4113.
13. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
14. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
15. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
16. Rini BI, Paintal A, Vogelzang NJ et al. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother 2002; 25: 269-277.
17. Gajewski TF, Pinnas M, Wong T, Fitch FW. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 1991; 146: 1750-1758.
18. Barbera-Guillem E, Nelson MB, Barr B et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000; 48: 541-549.
19. Rowley DA, Stach RM. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses. Int Immunol 1998; 10: 355-363.
20. Kirchner H, Chused TM, Herberman RB et al. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 1974; 139: 1473-1487.